Oncopeptides AB is a Swedish biotech company that, after a long development phase, has successfully developed and commercialized a drug called Pepaxti. This drug is intended for use in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have not responded adequately to previous treatments. The company went public in 2017 and, as often happens with these early-stage companies, the share price has collapsed since the listing. The road toward phase III was a grim one for shareholders of this company as well.
Now, however, we are in a situation where the drug has been commercialized. For a novice biotech investor, this is a situation where the focus can shift to marketing and cash flow, now that the drug is proven to work. In fact, the situation is ideal in the sense that the drug’s efficacy has now been established, and the focus is now on the company generating cash flow through this new drug. There aren’t many companies in this exact situation. Often, early-stage companies are dependent on funding rounds, or in the mature stage, patents are expiring and the concern is how price levels will crash as competition intensifies when generic drugs enter the market. I hope that this modest and brief introduction will nevertheless act like flypaper and attract this forum’s heavyweight biotech analysts to give their verdict on this company that has traveled such a long and hard road. A link to the company’s website is below, where there is naturally much more information about this company, which I believe definitely deserves a thread on the best investment portal in the Nordics.